Role of Programmed Cell Death Pathways in Mediating Epithelial Wound Healing and Its Defects in Diabetic Corneas
1Departments of Ophthalmology, Visual, and Anatomical Sciences, Wayne State University School of Medicine, Detroit, Michigan, United States.
Purpose:
Diabetic keratopathy (DK), a sight-threatening corneal disease, is characterized by delayed epithelial wound healing and ulceration. This study investigated the role of programmed cell death (PCD) pathways-caspase-mediated apoptosis and RIPK1/RIPK3-mediated necroptosis-in corneal wound healing in normal (NL) and diabetes mellitus (DM) B6 mice.
Methods:
Corneal epithelial debridement wounds were created in normoglycemic, streptozotocin (STZ)-induced, and db/db diabetic mice. Wound closure was quantified by digitizing the residual wound area. PCD pathway activity was assessed by RT-qPCR, immunohistochemistry (IHC), and whole-mount confocal microscopy. Pharmacologic inhibitors were applied to determine the role of specific PCD modulators in corneal wound healing.
Results:
In healing DM corneas, wounding-induced Casp8 upregulation was blunted, whereas RIPK3 upregulation was enhanced. At the tissue level, cleaved caspase-3 (c-Casp3, active) was more abundant in NL corneas, whereas phosphorylated RIPK3 (pRIPK3) predominated in DM corneas. The pRIPK3 was detected as early as 9 hours post-wounding in DM corneas, whereas c-Casp3 was most abundant at 72 hours post-wounding-a time point when PCD activity was no longer detectable in NL corneas. Pharmacologic inhibition of RIPK3 accelerated wound closure and suppressed inflammation in both NL and DM corneas, with greater benefit in DM corneas. Notably, extracellular HMGB1, a key alarmin/DAMP released during necroptosis, was strongly localized to basal cells. Blocking HMGB1 with glycyrrhizin, a cell-impermeable inhibitor, improved wound healing outcomes in DM corneas.
Conclusions:
Hyperglycemia skews PCD from apoptosis toward necroptosis. Targeting necroptosis or its downstream effectors, such as HMGB1, may represent a promising therapeutic approach for DK.
Insights
Diabetic corneas show a shift from apoptosis to necroptosis, hindering wound healing. Targeting necroptosis and HMGB1 offers a promising therapeutic strategy for diabetic keratopathy.
Area of Science:
- Ophthalmology
- Cell Biology
- Diabetic Complications
Background:
- Diabetic keratopathy (DK) impairs corneal wound healing.
- Programmed cell death (PCD) pathways, including apoptosis and necroptosis, are implicated.
Purpose of the Study:
- Investigate the roles of apoptosis and necroptosis in corneal wound healing in normal and diabetic mice.
- Assess the impact of hyperglycemia on PCD pathway activation.
Main Methods:
- Created corneal epithelial wounds in normal and diabetic mouse models.
- Quantified wound closure and assessed PCD pathway activity using molecular and imaging techniques.
- Utilized pharmacologic inhibitors to evaluate therapeutic targets.
Main Results:
- Diabetic corneas exhibited increased RIPK3-mediated necroptosis and decreased caspase-mediated apoptosis.
- RIPK3 inhibition accelerated wound healing and reduced inflammation in both normal and diabetic corneas.
- Blocking HMGB1, a necroptosis marker, improved wound healing in diabetic corneas.
Conclusions:
- Hyperglycemia promotes a shift from apoptosis to necroptosis in corneal wound healing.
- Targeting necroptosis or HMGB1 presents a potential therapeutic avenue for diabetic keratopathy.
Related Concept Videos
Diabetic Foot Ulcer
Diabetic Retinopathy
Diabetic Neuropathy
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Clinical Applications of Epidermal Stem Cells
Diabetic Nephropathy

